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Abstract
Background: Excessive Th1 cells and TLRs functions are involved in the pathogenesis of Behcet’s disease (BD) in
response to bacterial antigens. NOD2, an intracellular pathogen recognition sensor, modulates innate defence to
muropeptides derived from various bacterial species. To further define a role for NOD2 in BD, we analysed NOD2
transcriptional responses in BAL-MNC from BD patients with pulmonary manifestations.
Methods: We analysed NOD1, NOD2, T-bet and TLRs mRNA expression with real-time polymerase chain-reaction in
BAL cells obtained from 23 BD patients with pulmonary manifestations and their matched controls.
Results: We found that NOD2 mRNA expression was highly up-regulated in BAL cells from BD and sarcoidosis
patients compared to healthy control group (P = 0.001). In BD patients, significant correlation was found between
NOD2 and T-bet mRNA expression (r = 0.602; P = 0.0009). In BAL from BD patients, NOD2 and T-bet mRNA
expression were significantly correlated with BAL-lymphocytes (r = 0.485, P = 0.010; r = 0684, P = 0.0001
respectively). NOD2 in BD was also correlated with TLR 2(r = 0.444; P = 0.021) and TLR 4 (r = 0.574; P = 0.001) mRNA
expression.
Conclusion: Our results indicate that BAL-MNC from BD patients expressed NOD2 as a result of lung inflammation.
TLRs and NOD2 synergize for the induction of proinflammatory cytokines. BAL inflammatory cells showed an
increased Th1 situation as indicated by increased T-bet mRNA expression.
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Background
Behcet’s disease (BD) is a systemic vasculitis with
unknown aetiology. Immune dysregulation involving T
and B cells with hyperreactive neutrophils, supposedly
triggered by infectious agents, contribute to disease
pathogenesis in addition to genetic predisposition [1-3].
Documentation of various atypical streptococcal species
in oral flora of BD patients, clinical flares after dental
procedures, and a good response to antibacterial treat-
ment, have been considered as evidence for the role of
Streptococcus in BD [4]. However, none of the microbial
agents has been definitely proved to cause BD. Immuno-
logical disorders are important in BD pathogenesis [5].
T lymphocytes from patients with BD produced a parti-
cular inflammatory mediators pattern when stimulated
with a bacterial superantigen [6-9]. Innate immunity was
deeply investigated in BD patients [9,10]. Toll-like recep-
tor (TLR)-expressing cells (TLR-2 and TLR-4) [9] and
gamma delta T cells (TCRgδ) [11] have been involved in
BD inflammatory reactions.
NOD-like receptors (NLRs) are a family of innate
immune receptors that play key roles in host defence
and inflammation. NLR genes have been preserved
throughout evolution and at least 22 members are pre-
sent in humans [12]. NOD2 is an intracellular receptor
for the bacterial cell wall component muramyl dipeptide
(MDP), and variants of NOD2 are associated with
chronic inflammatory diseases of barrier organs (e.g.,
Crohn’s disease, asthma, and atopic eczema) [12,13]. It
is known that activation of NOD2 induces a variety of
inflammatory and antibacterial factors. Truncated
NOD2 proteins are encoded by mutations in the NOD2
gene that predispose individuals to inflammatory dis-
eases [14].
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monary manifestations, we analysed NOD2 mRNA tran-
scriptional responses in BAL (broncho-alveolar lavage)
and PBMC (peripheral blood mononuclear cells) har-
vested from BD patients with pulmonary manifestations,
sarcoidosis patients (disease controls) and healthy con-
trols. We correlated the transcriptional responses of
TLR2 and TLR4 with NOD1 and NOD2 in BD patients.
Methods
Patients and cell isolation
The study group consisted of 27 BD patients (19 male, 8
female), 10 sarcoidosis patients and 23 healthy indivi-
duals. All of the BD patients (age 34 ± 10 years; range
17-56 years) fulfilled the international study group cri-
teria for Behcet’s disease [15], had disease duration for
1-9 years (mean ± SD: 5.8 ± 3.4). Twenty tree BD
patients were never-smokers and 4 patients were ex-
smokers as certified. All patients had active BD with
pulmonary manifestations [16-18]. Clinical manifesta-
tions were eye lesions (14 patients: 51.85%) oral ulcer
(27 patients: 100%) genital ulcer (18 patients: 66.67%)
arthritis (16 patients: 59.25%) and vascular symptoms
(12 patients: 44.45%). Pulmonary vascular abnormalities
were as follows: asymptomatic functional abnormalities
(8 patients), pulmonary artery aneurysm of varying signs
(6 patients), pulmunary artery embolism (9 patients),
and pulmonary venous abnormalities (4 patients).
Remission was defined when clinical manifestations
were lost (eye lesions, oral ulcer, genital ulcer and
arthritis). Asymptomatic functional abnormalities dimin-
ished after corticosteroid treatment. BAL from ten
patients with sarcoidosis acted as disease controls (7
men and 3 women; median age 37 years; range: 28-47).
The diagnosis of sarcoidosis was determined in compli-
ance with the international criteria [19]. The control
subjects consisted of 23 non-smokers (18 men and 5
women; mean age: 42.8 ± 7 years; range: 38-52 years)
undergoing routine investigations for suspected bron-
chial carcinoma and whose chest X-ray (CXR), bronchial
examination, and pulmonary function were normal.
None of them had evidence of acute infection or
chronic disease (e.g., other autoimmune or atopic disor-
ders). Whole blood (10 BD patients) and BAL (BD-27
patients) were obtained after informed consent. Blood
samples (5 ml) were immediately transferred into PAX-
gene Blood RNA Tubes (Qiagen) for isolation and puri-
fication of intracellular RNA. Blood from ten active BD
patients (8 patients with asymptomatic functional
abnormalities and 2 patients with pulmonary artery
aneurysm of varying signs) were studied for NOD1 and
NOD2 mRNA expression before and after treatment.
Remission in these patients was started as they lost all
their clinical symptoms (eye lesions, oral ulcer, genital
ulcer and arthritis). Patients with asymptomatic func-
tional abnormalities lost these symptoms but not the
two patients who have pulmonary artery aneurysm.
They were treated with steroids and colchicine. Our
hospital ethic committee approved the design of the
study.
Bronchoalveolar lavage (BAL)
BAL was obtained as we previously reported [17,18].
Briefly, bronchoscopy was performed according to stan-
dard guidelines [18]. Thirty minutes prior to the proce-
dure patients received 0.5 mg of atropine and 12.5 mg
codeine intramuscularly. Local anaesthesia of the oro-
pharynx was achieved by xylocaine instillation until gag
reflexes subsided. Bronchoscopy was performed using a
Pentax bronchoscope through which 150 ml of normal
prewarmed saline in aliquots of 20 ml were instilled into
a subsegment of the right middle lobe. BAL fluid was
then immediately aspirated by gentle hand suction into
plastic tubes and kept at 4°C on ice.
BAL fluid was concentrated 10 fold before analysis
whilst a great part of the cell pellets were immediately
fixed in RNA stabilisation buffer. The total count of
nucleated cells was performed as we have recently
reported [20]. Differential cell counts were performed
on cytospin slides. Following Pappenheim staining, 300
cells per slide were counted. Lymphocyte counts in BAL
(Table 1) were confirmed by flow cytometry (10
4 gated
events) after staining 5 × 10
5 cells with anti CD4-FITC,
anti CD8-PE and anti CD3-PercP antibodies (BD Bios-
ciences, UK).
Anti-human macrophage, CD68 monoclonal antibody
(PG-M1) was used to characterize the macrophages phe-
notype recovered with BAL. The staining was performed
using a three-step, indirect immunoalkaline phosphatase
(ALP) method. Frozen slides were slowly warmed to
room temperature before processing. Slides were fixed in
-20°C acetone for 10 min and rehydrated for 5 min in
Tris-buffered saline (TBS), pH 7.6, containing 1% bovine
serum albumin (BSA). The slides were then incubated
with 80 μl of the appropriate dilutions of: CD68 mono-
clonal antibody, ALP-conjugated rabbit anti-mouse anti-
body (Dako, Glostrup, Denmark) and ALP-conjugated
swine anti-rabbit antibody (Dako), 30 min each. The
incubations took place in humid chambers and the sam-
ples were carefully washed with TBS between the steps.
The immunological reaction was visualized using freshly
prepared ALP substrate (Phosphatase Fast Red Sigma
solution, Sigma) containing 1 mmol/L levamisole (Sigma)
to inhibit endogenous macrophage ALP activity. The
enzyme-substrate reaction was interrupted with tap
water and the slides were counterstained with Harris
Haematoxylin (Histolab, Gothenburg, Sweden) for 30 s,
blued in tap water and air-dried. For mounting, Glycerine
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slides were viewed with a Nikon light microscope. The
macrophages were identified on the basis of morphologi-
cal features and positive cells were recognised by red
staining. An irrelevant monoclonal antibody (anti-human
cytokeratin; Dako) negative for macrophages was used to
assess background staining.
Reverse transcription and real-time PCR
RNA was isolated from whole blood and from lavage
cell pellets using the Paxgene
® and RNeasy
® Kit, respec-
tively. Reverse transcription and real-time PCR, to quan-
tify mRNA encoding for NOD2, NOD1, IL-4, IFN-g and
TLRs, were performed on samples, as previously
described [20], after quality control of RNA templates
[21]. mRNA values were normalised to a validated
housekeeping gene, human-acidic-ribosomal-protein
(HuPO) [22]. Primer and probe sequences are shown in
Table 2.
Quantification of T-bet gene expression by RT-PCR
The expression of mRNA was quantified using the
Applied Biosystems 7500 Fast Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA) as we have
recently reported [20]. Amplification of cDNA was per-
formed with the TaqMan Universal PCR Master Mix
(2×), No AmpErase UNG (Applied Biosystems). A reac-
tion volume of 25 μl (1.0 μl cDNA) was amplified for 40
cycles of 10 s at 95°C and 1 min at 60°C. All samples
were analysed in duplicate, and transcription expression
was calculated as a mean and standard deviation (SD).
For quantification of cDNA a five point serially four-
fold diluted standard curve was developed from CSF cell
cultures stimulated with phytohaemagglutinin (PHA).
The mRNA expression of the T cell transcription factors
was standardized to 18S (human rRNA) and all results
are expressed as a ratio. A coefficient of variance < 15%
was accepted as maximum variation among duplicates.
The intra-assay variance for 18S was 4.9%, and T-bet
6.2%. Samples revealing an undetectable expression in
both duplicates in three subsequent analyses were
assigned an expression quantity of zero. Primers and
probes for T-bet expression were analysed with Taq-
Man
® Gene Expression assays (Applied Biosystems).
The following sequences were used: T-bet (sense:
Table 1 Patients and controls characterization
BAL analysis Behçet’s Disease (n = 27) Sarcoidosis (n = 8) Healthy Controls
% Recovery 67 (59-77) 68 (65-74) 69 (63-76)
% Viability 95 (93-97) 94 (92-97) 92 (90-96)
Cell concentration (*10
6/L) 182 (150-320) ¤ 175 (110-325)¤ 120 (109-270)
Total cell number (*10
6/L) 23 (17-32)¤ 26 (18-40)¤ 15 (9-27)
BAL differential cell counts
% Macrophages 74 (58-77) 77 (62-84) 65 (55-67)
% Lymphocytes 19 (14-28)
¤ 22 (17-30)¤ 9 (7.5-12)
% Neutrophils 0.7 (0.5-1.2) 1.4 (0.9-1.8)¤ 0.4 (0.2-0.6)
% Eosinophils 0 (0-0.5) 0 (0-0.7) 0 (0-0.2)
CD4: CD8 ratio 4.2 ± 0.7 (3.8-5.4)¤ 6.5 (3.6-9.8)¤ 2.3 ± 0.5 (1.4-2.9)
copy number IFNg 2786 ± 748 (1097-3600)¤ 3247 ± 921 (2568-4500)¤ 18 ± 9.5 (12-127)
BAL Th1/Th2 ratio 4.5 ± 1.2 (2.8-5.3) ¤ 5.8 ± 4.3 (5.2-12.8) ¤ 1.3 ± 0.7 (0.5-1.9)
Values are presented as median ± SD (ranges) or median (range). (¤): Significance Behçet disease versus control subjects, (P = 0.001). BAL samples from 27 BD
patients with pulmonary involvement, 8 patients with sarcoidosis and 23 controls were investigated. The pulmonary arteries are the second most common site of
arterial involvement, preceded by the aorta. Aneurysms are more common than thrombosis.
Table 2 Primer and probe sequences used to quantify
gene expression by real-time polymerase chain reaction
(PCR)
Genes Δ Probe sequence 5’-(FAM - TAMRA)-3’ Product size
￿ L primer-5’-3’
■ R primer-5’-3’
IL-4 Δ AAACCTTCTGCAGGGCTGCGAC 71 bp
￿ GCTGCCTCCAAGAACACAAC
■ CTGTAGAACTGCCGGAGCAC
NOD1 Δ CCTGGCTCCGACATCGGTGA 133 bp
￿ AAGCGAAGAGCTGACCAAAT
■ TCCCAGTTTAAGATGCGTGA
NOD2 Δ CCGAGGCATCTGCAAGCTCA 82 bp
￿ CTGCAAGGCTCTGTATTTGC
■ CTCGCAGTGAAGAGCACATT
HuPO Δ TGCCAGTGTCTGTCTGCAGATTGG 105 bp
￿ GCTTCCTGGAGGGTGTCC
■ GGACTCGTTTGTACCCGTTG
TLR2 Δ GGAGTTCTCCCAGTGTTTGG 105 bp
￿ GCATTGTCCAGTGCTTCAAC
TLR4 Δ AGTGAGGATGATGCCAGGAT 147 bp
￿ TTCATGCCAGCTCTTCTGTG
HuPO: human acidic ribosomal protein; IL: interleukin.
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TGGTAGG CAGTCACG). HPLC-purified oligonucleo-
tide primers and probes were bought from MedProbe
(Oslo, Norway). All in-house designed mRNA amplicons
included at least one exon-exon boundary to assure spe-
cificity (marked in bold in the sequences above), and
reaction concentration was optimized prior to analysis
of samples.
Flow cytometry analysis
BAL cells were analyzed for expression of NOD1 and
NOD2 proteins on a Coulter Epics XL flow cytometer
(Beckman Coulter, INSERM 354, Paris, France) and
gated based on forward and side scatter properties. Data
were analyzed with the Expo32 ADC analysis software
(Beckman Coulter). To detect the intracellular NOD1
and NOD2, the IntraPrepTM Permeabilization reagent
kit was used according to instructions of the manufac-
turer (Beckman Coulter). Unlabeled NOD2 monoclonal
antibody (mAbs) was detected using the Alexa Fliuor
488 mouse IgG1 labelling kit (Momecular Probes,
E u g e n e ,O R ,U S A ) .T h er a b b it anti-human NOD1 pAb
was identified using a secondary fluorescein isothiocya-
nate (FITC)-conjugated goat anti-rabbit IgG pAb. Cells
were incubated with Abs for 30 min, thereafter washed
and resuspended in PBS (phosphate buffered saline).
Data analysis
Statistical analysis
All data are reported as medians (ranges, minimum to
maximum). Differences between groups were analyzed by
using the Wilcoxon signed-rank test or the Mann- Whit-
ney U test. Correlation was assessed using Spearman rank
test. A P value of less than 0.05 was considered significant.
Results
1. Broncho-alveolar lavage (BAL) fluid analyses
BAL fluids recovered from BD and sarcoidosis patients
were more cellular than healthy controls, containing sig-
nificantly greater number of lymphocytes (P < 0.05)
(Table 1). BD-BAL macrophage showed similar CD68
expression (33.46% ± 5.9%; range: 27-42) when compared
to BAL from healthy controls (35.47% ± 6.2%; range: 25 -
40; P >0.05). In contrast BAL-macrophages from sarcoi-
dosis patients expressed higher CD68 positive cells than
in BD (56.43% ± 9.8%; range 40 - 61.5; P = 0.0002). In
BAL-BD and sarcoidosis patients the Th1/Th2 (IFN-g/
IL-4) ratio and IFN-g mRNA levels were significantly ele-
vated compared to healthy controls (Table 1).
2. BAL from BD patients express NOD2 mRNA
NOD2 mRNA expression levels are elevated in pul-
monary leucocytes from BD and sarcoidosis patients and
differ significantly when compared to healthy controls
(Figure 1A). NOD2 mRNA was higher in sarcoidosis
patients than in BD patients (P = 0.0001). We also com-
pared the expression levels of NOD1 mRNA (also known
as CARD4), in pulmonary leucocytes obtained from BD
and sarcoidosis patients and healthy controls. NOD1 is
an intracellular protein that is closely related to NOD2.
No differences were observed in NOD1 expression
between BAL-BD patients, BAL-sarcoidosis patients and
BAL-healthy controls (Figure 1A). At the protein level, a
clear NOD2 up-regulation was observed in BAL of BD
patients. No NOD1 staining was seen (Figure 1B).
3. NOD2, and TLR2 and TLR4 mRNA expression cor-
relate in BAL-leucocytes in BD patients.
NOD2 regulates cellular responses to peptidoglycan-
mediated activation of TLR2 [23]. TLRs are associated
Figure 1 NOD1 and NOD2 mRNA expression in BAL leucocytes
obtained from Behçet’s disease (BD) patients.[ A]: NOD1 and
NOD2 mRNA expression in BAL from BD and sarcoidosis patients
compared to healthy controls. NOD1 and NOD2 mRNA expression
were measured by real-time RT-PCR. To permit comparison between
individuals, absolute copy numbers of NOD1 and NOD2 mRNA
were measured during RT-PCR, using cDNA standards, and
expressed relative to 10
6 mRNA copies of a validated housekeeping
gene, HuPO. [B]: Detection of NOD1 and NOD2 protein in
bronchoalveolar lavage cells from BD patients by flow cytometry.
Histograms shown are representative of two independent
experiments. Staining against NOD1 and NOD2 (open histogram),
appropriate isotype controls (light shaded histogram) or secondary
Abs (dark shaded histogram). Data show one representative out of
three independent experiments
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leucocytes obtained from BD patients, NOD2 mRNA
expression correlates significantly with TLR4 (r = 0.574;
P = 0.001) and TLR2 (r = 0.444; P = 0.021) (Figure 2A;
2B). In healthy controls, there was no correlation
between NOD2 and TLR2 or TLR4 mRNA expression
in BD-pulmonary leucocytes. NOD1 mRNA expression
correlates significantly with TLR2 (r = 0.489; P =
0.0095) and TLR4 (r = 0.574; P = 0.0017) mRNA
expression in pulmonary leucocytes obtained from BD
patients and healthy controls.
4. Quantification of T-bet mRNA expression in BAL
cells from BD patients
We evaluated mRNA expression of BAL samples from
BD patients and healthy controls (Figure 3). T-bet
mRNA was constitutively expressed in all BAL cell sam-
ples obtained from BD patients and healthy controls.
There was a significant increase of T-bet mRNA expres-
sion in BAL from BD patients compared to BAL from
healthy control (P = 0.001). We did not observe any dif-
ference in the number of T-bet transcripts and the dif-
ferent pulmonary manifestations in BD.
5. Correlation of T-bet mRNA expression with BAL
cellular profile in BD
In order to find out whether T-bet expression corre-
lates with the BAL cellular profile, we performed corre-
lation analysis. T-bet mRNA expression correlates with
BAL lymphocyte count (r = 0.684; P = 0.0001) in BD. A
low and significant correlation was observed between
BD-BAL macrophages and T-bet mRNA expression (r =
0.393; P = 0.045).
In patients with BD, a significant correlation was
found between NOD2 mRNA expression and BAL-lym-
phocytes (r = 0.485; P = 0.010). We did not find any
correlation between BAL-macrophages and NOD2
mRNA expression (r = 0.217; P >0.05). A strong correla-
tion was observed between T-bet and NOD2 mRNA
levels in BAL from BD patients (r = 0.602; P = 0.0009).
6. NOD2 expression in peripheral blood
NOD2 was increased in PBMC from BD patients
(791.90 ± 87.49) with low significance when compared
Figure 2 NOD2 mRNA expression correlates significantly with TLR2 and TLR4 mRNA expression in BAL leucocytes harvested from
Behcet’s Disease (BD) patients with pulmonary manifestations.[ A]: Significant correlation was observed between NOD2 and TLR4 mRNA
expression, and [B]: NOD2 and TLR2 mRNA expression. To permit correlations, absolute copy numbers of NOD2 and TLR2 and TLR4 mRNA were
measured during RT-PCR, using cDNA standards, and expressed relative to 10
6 mRNA copies of a validated housekeeping gene HuPO. NOD2
mRNA expression correlates significantly with TLR2 and TLR4 mRNA expression
Figure 3 Transcription factor expression folds change in BAL
from patients with Behçet’s Disease (BD), and healthy controls.
All values represent quotes between transcription factor and 18S
expression. In the figure, the horizontal bars within boxes correspond
to the median; box limits correspond to 25th and 75th percentiles and
vertical lines indicate the range. The mean values were compared and
the P values are indicated at the figure. Significant difference was
observed in T-bet value between BAL-BD patients and BAL-HC
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nificant difference was observed in NOD1 mRNA
expression between BD patients (624.30 ± 153.18) and
healthy controls (636.0 ± 160.2; P = 0.86) (Figure 4).
PBMC of 10 BD patients with pulmonary manifesta-
tions were tested for NOD1 and NOD2 mRNA expres-
sion before and after treatment (Figure 4). All 10 BD
patients were on colchicine (1-2 mg/day). Additionally,
7 patients received cyclosporine (5 patients received 50-
100 mg/day and 3 patients received 200 mg/day). NOD1
and NOD2 exhibited similar mRNA expression before
and after treatment.
No difference was observed in NOD1 mRNA expres-
sion before and after treatment. Significant differences
in NOD2 mRNA expression were observed in 3/10 BD
patients after treatment. These patients were character-
ized by receiving high dose of corticosteroids.
Discussion
Although the aetiology of BD is not yet known, it is
thought that genetic predisposition and immune dysre-
gulation are critical factors in the pathogenesis. Most of
the studies reported that BD is driven primarily by
proinflammatory and Th1 cytokines. NOD2 is a member
of the phylogenetically conserved NLR (NACHT-leu-
cine-rich repeat) family, that acts through NF-KB modu-
lation. To further define a role for NOD2 in BD with
pulmonary manifestations, we analysed NOD2 transcrip-
tional responses in pulmonary leucocytes and mononuc-
lear cells. As a systemic inflammatory disease,
sarcoidosis NOD2 mRNA expression in BAL was com-
pared to BAL from BD patients. NOD2 mRNA was
highly expressed in BAL from BD patients but at a
lower level than in sarcoidosis patients. The expression
of NOD2 protein was demonstrated in BAL cells using
flow cytometry. NOD2 mRNA expression correlated
with TLR2 and TLR4 mRNA expression in BD patients
with pulmonary manifestation. The increased NOD2
mRNA expression could be associated to inflammation
in the lung from BD patients.
T-bet is expressed preferentially by Th1 and natural
killer (NK) cells, and its expression correlates to some
extent with that of IFNg [26]. Numerically and function-
ally increased Th1 cells are implicated in the develop-
ment of a variety of auto-immune/inflammatory diseases
including BD. In comparison to control subjects, T-bet
mRNA expression was increased in BAL from BD
patients, suggesting a role for this transcription factor in
the immunopathogenesis of Th1 diseases. There is a
common agreement on the predominance of Th1 and
Th17 cytokines producing cells at the site of inflamma-
tion in BD [20,27,28]. Li et al. reported a significantly
increased T-bet mRNA expression in the peripheral cir-
culation of patients with active Behcet’s disease [29].
Increased levels of T-bet have been reported also in other
T h 1d i s e a s e ss u c ha sC r o h n ’s disease [30], sarcoidosis
[31] and celiac disease [32]. Recently Kriegova et al.
reported that T-bet was detected in lung macrophages
and lymphocytes [31]. NOD2 mRNA expression in BD-
BAL fluid was correlated with T-bet expression. In view
of the crucial role of T-bet in Th1 differentiation and
NOD2 mRNA upregulation, we hypothesized that they
were involved in the pathogenesis of BD-lung inflamma-
tion. Significant correlations were found between NOD2
mRNA expression, T-bet mRNA expression and BAL-
BD-lymphocytes.
Macrophages from BD patients expressed similar CD86-
positivity than healthy controls. In contrast sarcoidosis
patients showed a higher expression of CD68-positive
cells. CD68 is a good marker for alveolar macrophages
and it is not modulated in lung diseases as reported by St-
Laurent et al. [33]. According to this preliminary data, we
could speculate that macrophages from BD patients are
not directly implicated in the NOD2 production. However,
our conviction was that all inflammatory cells contribute
to BAL-immune cell activation: macrophages, lymphocytes
and dendritic cells [18,28]. Recently we reported that
BAFF levels were significantly increased in BAL fluid from
BD patients and that BAFF was produced locally in the
lower airway of active BD. In the same way IL-6 and IL-13
were also produced locally, and their concentrations were
Figure 4 Comparative analysis of NOD1 and NOD2 mRNA
expression in peripheral blood mononuclear cells (PBMC)
obtained from 10 active Behcet disease (BD) patients with
pulmonary manifestations before and after treatment after
their symptoms had resolved. NOD1 and NOD2 mRNA expression
was analysed, by real-time RT-PCR, in peripheral blood cells isolated
from BD patients and matched controls. To permit comparison
between individuals, absolute copy numbers of NOD1 and NOD2
mRNA were measured during RT-PCR, using cDNA standards, and
expressed relative to 10
6 mRNA copies of a validated housekeeping
gene HuPO. NOD2 in 3/10 patients but not NOD1 mRNA levels
increased significantly after treatment. Statistical significance was
evaluated by the Wilcoxon test
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from BD patients with lung involvement [18].
Autoinflammatory diseases were characterized by see-
mingly unprovoked episodes of inflammation, without
high levels of autoantibodies or antigen-specific T cells,
and derive from genetic variants of the innate immune
system. Categories of autoinflammatory diseases were
associated with NOD2 gene mutation [34]. BD shares
clinical features with autoinflammatory disorders [35]. In
these autoinflammatory diseases, IL-1b,I L - 6a n dT N F - a
are key cytokines responsible in autoinflammatory disor-
ders. These cytokines and their genetic polymorphism
were highly associated with the inflammation in BD
patients [5].
Normal levels of NOD2 mRNA expression were found
in peripheral leucocytes from BD patients. We hypothesise
that this could have been due to translocation of antigen-
specific leucocytes predominantly to the site of disease
(lung) with few NOD2 expressing leucocytes in the per-
ipheral compartment. We might expect this to occur in
parallel with TNF-a as this cytokine up-regulates NOD2
mRNA expression in various cell lineages including PBMC
[36]. In keeping with these data, increased TNF-a mRNA
expression in BD patients was reported [37]. Akmen et al.
[38] reported that TNF-alpha-1031 C allele is associated
with susceptibility to BD. They hypothesize that it has a
functional effect and could explain the high levels of TNF-
alpha production observed in BD patients. The relation-
ship between NOD2 and soluble TNF-a receptors must
be investigated.
Crohn’s disease (CD) has been associated with two SNPs
and a frameship mutation of the CARD15 gene [12].
Despite pathological similarities between BD and CD, con-
trasting results were reported in BD. Depending on the
studied population, no associations as well as negative
associations were reported [39,40]. Kappen et al. [41]
o b s e r v e das i g n i f i c a n t l yl o w e rf r e q u e n c yo ft w ov a r i a n t
alleles (Arg702Trp and Leu1007fs) in the BD group as
compared with healthy controls. As far, no genetics basis
seems involved in surexpression of NOD2 in BD. The
complex role of NOD2 in response to bacterial challenge
in different cell types should be addressed in BD and other
inflammatory conditions. NOD2 variants react in some
cases with a decreased production of inflammatory cyto-
kines to an exogenous stimulus. This is supported by the
observation that NOD2 gene-deficient mice show reduced
joint inflammation, and are protected against early carti-
lage damage after IA injection of Streptococcus pyogenes
cell wall fragments [42]
Tissue repair and remodelling are crucial to the
pathogenesis of lung inflammation as well as to host
defence, and based on data reported by Lafferty et al.
[43], it appears that TLR-dependent mechanisms med-
iate the development of both processes. In Behcet’s
disease NOD2 and TLRs appear to serve as indepen-
dent, pattern recognition receptor of unknown antigens.
Recently as reported by Nara et al. [9] TLR-2-expressing
cells as well as TLR-4-expressing cells were accumulated
in the intestinal lesions of BD. Durrani et al. [44] inves-
tigated TLR expression in BD tissue and found it
increased in buccal lesions. Similar results were
observed in patients with lichen planus or pyogenic
granuloma, suggesting that this was a generalized
inflammatory response as opposed to a BD-specific
response [44]. The initiating cause of BD is unknown,
but an aberrant response to infection has been sug-
gested [45]. Because TLRs are likely to be involved in
the pathogenesis BD [9,24,25,44], further investigation
of molecular mechanisms, including interactions
between TLRs and NOD2, are required, especially those
that distinguish BD from other inflammatory diseases.
This study has limitations. First, we have used RT-PCR
measurement of T-bet and NOD2 ex vivo to provide
information about their possible relationship in BD with
pulmonary manifestations, but we did not prove the
mechanism of interaction between these related genes by
functional studies. Secondly, this study focused on the
NOD mRNA expression profiles only in BAL cells and
not in lung parenchyma. Third, NOD2 and T-bet must
be investigated in purified BAL-cells: macrophages and T
lymphocytes. However, important preliminary data were
found. Significant correlations between NOD2 and T-bet
mRNA expression and T-bet mRNA expression and
BAL-lymphocytes count were found.
Conclusions
In summary, this is the first study suggesting implication
of T-bet, TLRs and NOD2 system in BAL-BD patients.
It is clear that BD is a complex disorder with possible
involvement of multiple genes and pathways along with
contribution from environmental factors. Proteins regu-
lating the inflammation process via the NF-KB pathway
are probably essential in Behçet’s disease pathogenesis.
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